Supernus Pharmaceuticals Disclosed That The US Food And Drug Administration (FDA) Has Acknowledged The Resubmission Of The New Drug Application (NDA) For The Continuous Treatment Of Motor Fluctuations In Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has announced that the US FDA has acknowledged the resubmission of the New Drug Application (NDA) for the continuous treatment of motor fluctuations in Parkinson's disease.

November 02, 2023 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals' resubmission of the NDA for Parkinson's disease treatment has been acknowledged by the FDA. This could potentially lead to a positive impact on the company's stock.
The acknowledgement of the NDA resubmission by the FDA is a positive development for Supernus Pharmaceuticals. It indicates that the company is making progress in its efforts to get approval for its Parkinson's disease treatment. This could potentially lead to increased revenues for the company if the drug is approved, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100